29 May 2015 - Oncology company Aduro Biotech (NasdaqGS:ADRO) stated on Thursday its net loss of USD16.6m for the first quarter ended 31 March 2015.This marks a decline in earnings when compared with a lower net loss of USD7.8m for the corresponding period in 2014.Revenue of USD9.6m was collected for the first quarter of 2015, up over revenues of USD25,000 for the same period in 2014, primarily due to recognition of a portion of the upfront fees and development-related milestones achieved under the Janssen agreements.Research and development (R&D) expenses of USD10.6m was recorded for the first quarter of 2015, a rise against R&D of USD4.7m for the same period in 2014, primarily due to clinical and manufacturing expenses related to the Phase 2b ECLIPSE clinical trial of CRS-207/GVAX Pancreas immunotherapy in pancreatic cancer as well as compensation costs due to growth in personnel.